A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma
Vid Mlakar, Edouard Morel, Simona Jurković Mlakar, Marc Ansari, Fabienne Gumy‐Pause
Abstract
Neuroblastoma is the most common extra-cranial solid tumor in children, representing approximately 8% of all malignant childhood tumors and 15% of pediatric cancer-related deaths. Recent sequencing and transcriptomics studies have demonstrated the RAS-MAPK pathway's contribution to the development and progression of neuroblastoma. This review compiles up-to-date evidence of this pathway's involvement in neuroblastoma. We discuss the RAS-MAPK pathway's general functioning, the clinical implications of its deregulation in neuroblastoma, and current promising therapeutics targeting proteins involved in signaling.
Topics & Concepts
NeuroblastomaMAPK/ERK pathwayCancer researchMedicineTranscriptomeSignal transductionApoptosisChildhood cancerBioinformaticsBiologyOncologyCancerInternal medicineGeneGeneticsGene expressionCell cultureNeuroblastoma Research and TreatmentsCell death mechanisms and regulationMicrotubule and mitosis dynamics